iShares Biotechnology ETF
Find Ratings Reports- Last Ratings Update:02/29/2024
- Price as of 02/29/2024 :$136.84
- Net Assets:$0 Million
- NAV:$139.79
- Premium-2.11%
- Peer Rank:25 of 48
- Investment Rating:D+
- Performance:D+
- RiskC+
We rate iShares Biotechnology at D+. Negative factors that influence this rating include a below average total return. The fund invests approximately 100% of its assets in stocks and may be considered for investors seeking a Sector - Health/Biotechnology strategy.
Total return ranks below peers over the last three years. The iShares Biotechnology has returned an annual rate of 6.51% since inception. More recently, the fund has generated a total return of 5.44% in the last five years, -2.09% in the last three years, and 7.41% in the last year. How does that compare to other equity funds? In the last five years, it has outperformed 50% of them. It has also outpaced 25% of its competitors on a three year basis and 40% of them over the last year for the period ending 2/29/2024. On a year to date basis, IBB has returned 2.91%.
Downside risk has been below average. IBB has a draw down risk of -34.01%, which is the largest price decline experienced over the last three years. This fund has a three year standard deviation of 19.2%. This fund has experienced a high level of volatility in its monthly performance over the last 36 months.
Low expense ratio helps performance. As IBB is an exchange traded fund, it has no front end or back end load.
The iShares Biotechnology is managed by Gregory R Savage at BlackRock Fund Advisors. This fund is one of 353 BlackRock Fund Advisors exchange-traded funds launched since 3/12/1996 that we track.